GestVision reports researchers have demonstrated that CRD (Congo Red Dot) urine diagnostic test results strongly correlate with a diagnosis of preeclampsia.
“This is an important study,” said Wendy L. Davis, MBA, Founder and CEO of GestVision. “The finding that the CRD test was superior to other tests used as the standard of care for preeclampsia assessment indicates further development and clinical studies are warranted.”
GestVision operates from BioCT Innovations Commons, the wet lab incubator with coworking office space in Groton. “We are very proud of GestVision, one of our first resident companies,” said Kim Kelly, Operating Director.